Cargando…
Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types
BACKGROUND: In 2008, a national human papillomavirus (HPV) immunisation programme began in Scotland for 12–13 year old females with a three-year catch-up campaign for those under the age of 18. Since 2008, three-dose uptake of bivalent vaccine in the routine cohort aged 12–13 has exceeded 90% annual...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037824/ https://www.ncbi.nlm.nih.gov/pubmed/24736582 http://dx.doi.org/10.1038/bjc.2014.198 |
_version_ | 1782318289004789760 |
---|---|
author | Kavanagh, K Pollock, K G J Potts, A Love, J Cuschieri, K Cubie, H Robertson, C Donaghy, M |
author_facet | Kavanagh, K Pollock, K G J Potts, A Love, J Cuschieri, K Cubie, H Robertson, C Donaghy, M |
author_sort | Kavanagh, K |
collection | PubMed |
description | BACKGROUND: In 2008, a national human papillomavirus (HPV) immunisation programme began in Scotland for 12–13 year old females with a three-year catch-up campaign for those under the age of 18. Since 2008, three-dose uptake of bivalent vaccine in the routine cohort aged 12–13 has exceeded 90% annually, while in the catch-up cohort overall uptake is 66%. METHODS: To monitor the impact of HPV immunisation, a programme of national surveillance was established (pre and post introduction) which included yearly sampling and HPV genotyping of women attending for cervical screening at age 20. By linking individual vaccination, screening and HPV testing records, we aim to determine the impact of the immunisation programme on circulating type-specific HPV infection particularly for four outcomes: (i) the vaccine types HPV 16 or 18 (ii) types considered to be associated with cross-protection: HPV 31, 33 or 45; (iii) all other high-risk types and (iv) any HPV. RESULTS: From a total of 4679 samples tested, we demonstrate that three doses (n=1100) of bivalent vaccine are associated with a significant reduction in prevalence of HPV 16 and 18 from 29.8% (95% confidence interval 28.3, 31.3%) to 13.6% (95% confidence interval 11.7, 15.8%). The data also suggest cross-protection against HPV 31, 33 and 45. HPV 51 and 56 emerged as the most prevalent (10.5% and 9.6%, respectively) non-vaccine high-risk types in those vaccinated, but at lower rates than HPV 16 (25.9%) in those unvaccinated. CONCLUSIONS: This data demonstrate the positive impact of bivalent vaccination on the prevalence of HPV 16, 18, 31, 33 and 45 in the target population and is encouraging for countries which have achieved high-vaccine uptake. |
format | Online Article Text |
id | pubmed-4037824 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-40378242015-05-27 Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types Kavanagh, K Pollock, K G J Potts, A Love, J Cuschieri, K Cubie, H Robertson, C Donaghy, M Br J Cancer Epidemiology BACKGROUND: In 2008, a national human papillomavirus (HPV) immunisation programme began in Scotland for 12–13 year old females with a three-year catch-up campaign for those under the age of 18. Since 2008, three-dose uptake of bivalent vaccine in the routine cohort aged 12–13 has exceeded 90% annually, while in the catch-up cohort overall uptake is 66%. METHODS: To monitor the impact of HPV immunisation, a programme of national surveillance was established (pre and post introduction) which included yearly sampling and HPV genotyping of women attending for cervical screening at age 20. By linking individual vaccination, screening and HPV testing records, we aim to determine the impact of the immunisation programme on circulating type-specific HPV infection particularly for four outcomes: (i) the vaccine types HPV 16 or 18 (ii) types considered to be associated with cross-protection: HPV 31, 33 or 45; (iii) all other high-risk types and (iv) any HPV. RESULTS: From a total of 4679 samples tested, we demonstrate that three doses (n=1100) of bivalent vaccine are associated with a significant reduction in prevalence of HPV 16 and 18 from 29.8% (95% confidence interval 28.3, 31.3%) to 13.6% (95% confidence interval 11.7, 15.8%). The data also suggest cross-protection against HPV 31, 33 and 45. HPV 51 and 56 emerged as the most prevalent (10.5% and 9.6%, respectively) non-vaccine high-risk types in those vaccinated, but at lower rates than HPV 16 (25.9%) in those unvaccinated. CONCLUSIONS: This data demonstrate the positive impact of bivalent vaccination on the prevalence of HPV 16, 18, 31, 33 and 45 in the target population and is encouraging for countries which have achieved high-vaccine uptake. Nature Publishing Group 2014-05-27 2014-04-15 /pmc/articles/PMC4037824/ /pubmed/24736582 http://dx.doi.org/10.1038/bjc.2014.198 Text en Copyright © 2014 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Epidemiology Kavanagh, K Pollock, K G J Potts, A Love, J Cuschieri, K Cubie, H Robertson, C Donaghy, M Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types |
title | Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types |
title_full | Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types |
title_fullStr | Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types |
title_full_unstemmed | Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types |
title_short | Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types |
title_sort | introduction and sustained high coverage of the hpv bivalent vaccine leads to a reduction in prevalence of hpv 16/18 and closely related hpv types |
topic | Epidemiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037824/ https://www.ncbi.nlm.nih.gov/pubmed/24736582 http://dx.doi.org/10.1038/bjc.2014.198 |
work_keys_str_mv | AT kavanaghk introductionandsustainedhighcoverageofthehpvbivalentvaccineleadstoareductioninprevalenceofhpv1618andcloselyrelatedhpvtypes AT pollockkgj introductionandsustainedhighcoverageofthehpvbivalentvaccineleadstoareductioninprevalenceofhpv1618andcloselyrelatedhpvtypes AT pottsa introductionandsustainedhighcoverageofthehpvbivalentvaccineleadstoareductioninprevalenceofhpv1618andcloselyrelatedhpvtypes AT lovej introductionandsustainedhighcoverageofthehpvbivalentvaccineleadstoareductioninprevalenceofhpv1618andcloselyrelatedhpvtypes AT cuschierik introductionandsustainedhighcoverageofthehpvbivalentvaccineleadstoareductioninprevalenceofhpv1618andcloselyrelatedhpvtypes AT cubieh introductionandsustainedhighcoverageofthehpvbivalentvaccineleadstoareductioninprevalenceofhpv1618andcloselyrelatedhpvtypes AT robertsonc introductionandsustainedhighcoverageofthehpvbivalentvaccineleadstoareductioninprevalenceofhpv1618andcloselyrelatedhpvtypes AT donaghym introductionandsustainedhighcoverageofthehpvbivalentvaccineleadstoareductioninprevalenceofhpv1618andcloselyrelatedhpvtypes |